Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study.

ABSTRACT:

Aims

To investigate the putative association between semaglutide and non-arteritic anterior ischaemic optic neuropathy (NAION).

Materials and methods

Data from national health registries in Denmark (2018-2024) and Norway (2018-2022) were used to compare NAION risk in individuals with type 2 diabetes initiating semaglutide versus sodium-glucose co-transporter 2 inhibitors (SGLT-2is). A supplementary self-controlled analysis examined NAION risk among all semaglutide users. National estimates were pooled using a fixed-effects model.

Results

We identified 44 517 users of semaglutide for the management of type 2 diabetes in Denmark and 16 860 in Norway, with a total of 32 NAION events observed. The unadjusted incidence rate of NAION was 2.19/10 000 person-years among Danis

SUBMITTER: Simonsen E 

PROVIDER: S-EPMC12046482 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature